北京佰仁医疗科技股份有限公司2025年度业绩快报公告

Core Viewpoint - The company reported a significant increase in revenue and net profit for the fiscal year 2025, demonstrating strong operational resilience and effective cost control measures. Financial Data and Indicators - The preliminary financial data for 2025 shows total revenue of 630.372 million RMB, representing a year-on-year growth of 25.60% [4] - The net profit attributable to the parent company reached 200.1903 million RMB, marking a 36.81% increase compared to the previous year [4] - The total assets at the end of the reporting period were 1,623.6085 million RMB, up 13.47% year-on-year, while the equity attributable to the parent company increased by 6.43% to 1,333.1676 million RMB [4] Operational Performance and Financial Condition - The company leveraged its innovation platform for implant materials and devices, resulting in strong performance across multiple product lines, particularly in the structural heart disease segment, which grew by 26.07%, and the soft tissue repair segment, which grew by 24.23% [4] - The company maintained effective control over management and sales expenses while continuing high levels of R&D investment, achieving a net profit margin of 30.69% after excluding share-based payment impacts [4] - The company submitted eight product registration applications during the reporting period, with three new products approved, including those that fill domestic market gaps [4] Changes in Key Financial Metrics - Operating profit increased by 45.78%, with total profit and net profit attributable to the parent company growing by 44.25% and 36.81%, respectively [5] - The growth in operating profit was attributed to strong sales of core products, effective cost control, and a reduction in share-based payment expenses, along with increased government subsidies [6]